Anne E. de Papp

3.8k total citations · 2 hit papers
36 papers, 2.9k citations indexed

About

Anne E. de Papp is a scholar working on Orthopedics and Sports Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Anne E. de Papp has authored 36 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Orthopedics and Sports Medicine, 26 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in Anne E. de Papp's work include Bone health and osteoporosis research (30 papers), Bone health and treatments (25 papers) and Bone Metabolism and Diseases (11 papers). Anne E. de Papp is often cited by papers focused on Bone health and osteoporosis research (30 papers), Bone health and treatments (25 papers) and Bone Metabolism and Diseases (11 papers). Anne E. de Papp collaborates with scholars based in United States, Canada and United Kingdom. Anne E. de Papp's co-authors include Erluo Chen, Richard A. Petruschke, Neil Binkley, Mary K. Beard, Ethel S. Siris, Aliya Khan, Michael F. Holick, Elizabeth Rosenberg, Andrew F. Stewart and Risa Kagan and has published in prestigious journals such as Endocrine Reviews, The Journal of Clinical Endocrinology & Metabolism and The American Journal of Medicine.

In The Last Decade

Anne E. de Papp

35 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prevalence of Vitamin D Inadequacy among Postmenopausal North American Women Receiving Osteoporosis Therapy

2005 700 citations Neil Binkley, Richard A. Petruschke et al. The Journal of Clinical Endocrinology & Metabolism profile →
Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials

2019 223 citations Mary Bouxsein, Richard Eastell et al. Journal of Bone and Mineral Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anne E. de Papp United States	22	1.9k	1.2k	1.0k	770	394	36	2.9k
L. Sinigaglia Italy	33	1.5k 0.8×	778 0.7×	669 0.7×	566 0.7×	316 0.8×	99	3.6k
Francesco Bertoldo Italy	33	1.2k 0.6×	876 0.8×	511 0.5×	542 0.7×	200 0.5×	90	2.6k
Harold N. Rosen United States	25	1.4k 0.7×	789 0.7×	344 0.3×	672 0.9×	324 0.8×	68	2.6k
K.E. Naylor United Kingdom	19	1.2k 0.7×	772 0.7×	419 0.4×	586 0.8×	162 0.4×	30	2.0k
Luca Idolazzi Italy	35	872 0.5×	611 0.5×	572 0.6×	662 0.9×	167 0.4×	143	3.2k
Marjorie M. Luckey United States	25	2.6k 1.4×	1.2k 1.0×	619 0.6×	846 1.1×	109 0.3×	31	3.5k
Angelo A. Licata United States	26	2.1k 1.1×	1.6k 1.4×	392 0.4×	918 1.2×	87 0.2×	72	3.4k
A. Joseph Foldes Israel	16	1.7k 0.9×	949 0.8×	266 0.3×	595 0.8×	95 0.2×	30	2.4k
Gerolamo Bianchi Italy	26	1.2k 0.6×	556 0.5×	393 0.4×	421 0.5×	115 0.3×	81	2.1k
Barbara P. Lukert United States	26	1.6k 0.9×	977 0.8×	585 0.6×	830 1.1×	181 0.5×	64	3.3k

Countries citing papers authored by Anne E. de Papp

Since Specialization

Citations

This map shows the geographic impact of Anne E. de Papp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne E. de Papp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne E. de Papp more than expected).

Fields of papers citing papers by Anne E. de Papp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne E. de Papp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne E. de Papp. The network helps show where Anne E. de Papp may publish in the future.

Co-authorship network of co-authors of Anne E. de Papp

This figure shows the co-authorship network connecting the top 25 collaborators of Anne E. de Papp. A scholar is included among the top collaborators of Anne E. de Papp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne E. de Papp. Anne E. de Papp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Binkley, Neil, Diane Krueger, & Anne E. de Papp. (2018). Multiple vertebral fractures following osteoporosis treatment discontinuation: a case-report after long-term Odanacatib. Osteoporosis International. 29(4). 999–1002. 7 indexed citations

2.

Bauer, Douglas C., Dennis M. Black, Mary Bouxsein, et al.. (2018). Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression. Journal of Bone and Mineral Research. 33(4). 634–642. 49 indexed citations

3.

Brixen, Kim, Roland Chapurlat, Angela M. Cheung, et al.. (2013). Bone Density, Turnover, and Estimated Strength in Postmenopausal Women Treated With Odanacatib: A Randomized Trial. The Journal of Clinical Endocrinology & Metabolism. 98(2). 571–580. 95 indexed citations

4.

Boyce, Brendan F., Elizabeth Rosenberg, Anne E. de Papp, & Le T. Duong. (2012). The osteoclast, bone remodelling and treatment of metabolic bone disease. European Journal of Clinical Investigation. 42(12). 1332–1341. 144 indexed citations

5.

Engelke, Klaus, B. Stampa, Wolfram Timm, et al.. (2011). Short-term in vivo precision of BMD and parameters of trabecular architecture at the distal forearm and tibia. Osteoporosis International. 23(8). 2151–2158. 63 indexed citations

6.

Folkesson, Jenny, Julio Carballido‐Gamio, Galateia J. Kazakia, et al.. (2010). Longitudinal evaluation of the effects of alendronate on MRI bone microarchitecture in postmenopausal osteopenic women. Bone. 48(3). 611–621. 34 indexed citations

7.

Bonnick, Sydney Lou, et al.. (2008). DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass. Osteoporosis International. 20(6). 911–921. 35 indexed citations

8.

Papp, Anne E. de, Henry G. Bone, Michael P. Caulfield, et al.. (2007). A cross-sectional study of bone turnover markers in healthy premenopausal women. Bone. 40(5). 1222–1230. 83 indexed citations

9.

Bonnick, Sydney Lou, Kenneth G. Saag, Douglas P. Kiel, et al.. (2006). Comparison of Weekly Treatment of Postmenopausal Osteoporosis with Alendronate Versus Risedronate Over Two Years. Obstetrical & Gynecological Survey. 62(1). 35–36. 5 indexed citations

10.

Rosen, Clifford J., Marc C. Hochberg, Sydney Lou Bonnick, et al.. (2005). Treatment With Once-Weekly Alendronate 70 mg Compared With Once-Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double-Blind Study. Journal of Bone and Mineral Research. 20(1). 141–151. 21 indexed citations

11.

Cryer, Byron, Neil Binkley, Christine Simonelli, et al.. (2005). A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis. The American journal of geriatric pharmacotherapy. 3(3). 127–136. 13 indexed citations

12.

Cryer, Byron, et al.. (2005). Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non‐steroidal anti‐inflammatory drug use. Alimentary Pharmacology & Therapeutics. 21(5). 599–607. 17 indexed citations

13.

Rosen, Clifford J., Marc C. Hochberg, Sydney Lou Bonnick, et al.. (2005). Treatment With Once-Weekly Alendronate 70 mg Compared With Once-Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double-Blind Study. Journal of Bone and Mineral Research. 20(1). 141–151. 261 indexed citations

14.

Sebba, Anthony, Sydney Lou Bonnick, Risa Kagan, et al.. (2004). Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Current Medical Research and Opinion. 20(12). 2031–2041. 44 indexed citations

15.

Luckey, Marjorie M., Risa Kagan, Susan L. Greenspan, et al.. (2004). Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis*. Menopause The Journal of The North American Menopause Society. 11(4). 405–415. 44 indexed citations

16.

Singh, Reetu, Marluce Bibbo, Mary F. Cunnane, J. Andrew Carlson, & Anne E. de Papp. (2002). Metastatic Cervical Carcinoma With Ectopic Calcitonin Production Presenting as a Thyroid Mass. Endocrine Practice. 8(1). 50–53. 8 indexed citations

17.

Greenspan, Susan L., Richard P. Tonino, Mary E. Smith, et al.. (2002). Tolerability of Once-Weekly Alendronate in Patients With Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Study. Mayo Clinic Proceedings. 77(10). 1044–1052. 70 indexed citations

18.

Orloff, John J., et al.. (1994). Parathyroid Hormone-Related Protein as a Prohormone: Posttranslational Processing and Receptor Interactions*. Endocrine Reviews. 15(1). 40–60. 165 indexed citations

19.

Papp, Anne E. de, et al.. (1994). Parathyroid carcinoma arising from parathyroid hyperplasia: Autoinfarction following intravenous treatment with pamidronate. The American Journal of Medicine. 97(4). 399–400. 17 indexed citations

20.

Papp, Anne E. de & Andrew F. Stewart. (1993). Parathyroid hormone-related protein a peptide of diverse physiologic functions. Trends in Endocrinology and Metabolism. 4(6). 181–187. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact